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Abstract In this study, the role of V12-Rac1 in the cisplatin-
induced apoptosis was investigated. Cisplatin-induced apoptosis
is associated with cytochrome c release, which can be inhibited
by V12-Rac1 expression. The analysis of mitogen-activated
protein kinase activity indicated that V12-Rac1 expression led
to a decrease in p38 activity after exposure to cisplatin but not
c-jun N-terminal kinase and extracellular signal-regulated
kinase. Using pharmacological inhibitors, it was found that
only p38 is a critical mediator in the cisplatin-induced apoptosis
of NIH3T3 cells. This suggests that V12-Rac1 can stimulate the
anti-apoptotic signaling pathway in response to cisplatin, and
that decreased p38 activity caused by V12-Rac1 expression in
cisplatin-treated NIH3T3 cells is crucial for V12-Rac1-depen-
dent cell survival. ß 2002 Published by Elsevier Science B.V.
on behalf of the Federation of European Biochemical Societies.
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1. Introduction
Rac is activated by growth factors and transmits these sig-
nals to the downstream e¡ectors [1^3]. Rac activation induces
a reorganization of the actin cytoskeleton, cell cycle progres-
sion, gene transcription, and membrane transport [4]. Rac has
also been shown to modulate the apoptosis induction path-
way, resulting in either pro-survival or pro-apoptotic func-
tions. Although a number of studies concerning the e¡ects
of Rac on modulating apoptosis have been reported, the
role of Rac in modulating apoptosis is unclear. Several studies
reported that Rac stimulates Bcl-2 expression in T and epi-
thelial cells [5,6], and constitutive Rho GTPases activation
prevents UV-induced apoptosis in epithelial cells [7]. Simi-
larly, constitutively active Rac provides a survival signal
under various stimuli in neurons, ¢broblasts, epithelial cells
and hematopoietic cells [8^13]. However, others have sug-
gested that active Rac GTPase overexpression is involved in
apoptosis in neurons, ¢broblasts and epithelial cells [14^19].
Such di¡erential e¡ects of Rac on modulating apoptosis can
re£ect the cell type- and extracellular stimuli speci¢city.
Therefore, the question as to whether or not the Rac1 protein
may be involved in regulating cisplatin-induced apoptosis was
directly addressed. Because Rac is a downstream e¡ector of
the oncogenic Ras, which is known to participate in carcino-
genesis in many human cancers [20], understanding the mo-
lecular basis of Rac-modulated apoptosis could lead to strat-
egies to improve the anti-cancer therapeutic bene¢ts.
Cisplatin is one of the most e¡ective and widely used anti-
cancer agents for a variety of human cancers [21]. Cisplatin
causes the formation of various reaction products with DNA
including covalent DNA adducts and DNA crosslinking, re-
sulting in cell cycle arrest [22], increased DNA repair activity
[23^25] and apoptosis [26,27]. Although the detailed mecha-
nisms by which such DNA damage stimulates apoptosis are
unclear, recent studies have shown that mitogen-activated
protein kinases (MAPKs) including extracellular signal-regu-
lated kinases (ERKs), c-jun N-terminal kinases (JNKs) and
p38 may be involved in the cellular cytotoxicity in response to
cisplatin [28^31].
In this paper, we show that V12-Rac1 prevents cisplatin-
induced apoptosis and decreases the p38 MAP kinase activity
of NIH3T3 cells stimulated by cisplatin. Furthermore, the p38
MAP kinase inhibitor, and not the JNK and ERK inhibitors,
attenuates cisplatin-induced apoptosis.
2. Materials and methods
2.1. Cell lines, antibodies, oligonucleotides and reagents
The NIH3T3 cells were obtained from the ATCC (Manassas, VA,
USA) and were maintained in Dulbecco’s modi¢ed Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM
L-glutamine, 100 U of penicillin/ml, and 100 Wg of streptomycin/ml
(Life Technologies, Inc.). The JNK antisense oligonucleotides used in
this study were synthesized at ISIS Pharmaceuticals, Inc. (Carlsbad,
CA, USA). The oligonucleotide sequences used are as follows: control
(ISIS 17552), TCAGTAATAGCCCCACATGG; JNK1 (ISIS 15347),
CTCTGTAGGCCCGCTTGG; JNK2 (ISIS 15354), GTCCGGG-
CCAG-GCCAAAGTC. Cisplatin and propidium iodide (PI) were
purchased from Sigma. The MAPK kinase (MEK) (U0126) and
p38 inhibitors (SB203580) were obtained from CalBiochem (San Die-
go, CA, USA). The anti-cytochrome c antibodies were purchased
from Transduction Laboratories (Lexington, KY, USA). The anti-
p38, anti-phospho-p38, anti-JNK, anti-phospho-JNK, anti-ERK and
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anti-phospho-ERK antibodies were all purchased from New England
Biolabs, Inc. (Beverly, MA, USA).
2.2. Cell culture
The NIH3T3 mouse embryo ¢broblast line was obtained from the
ATCC (Manassas, VA, USA) and was maintained in DMEM supple-
mented with 10% FBS, 2 mM L-glutamine, 100 U of penicillin/ml, and
100 Wg of streptomycin/ml (Life Technologies, Inc.). The cells were
cultured at 37‡C in a humidi¢ed chamber containing 5% CO2.
2.3. Plasmid constructs
The wild-type Rac1 cDNA was cloned by reverse transcription-
PCR from human Jurkat cells. The dominant positive form of Rac1
(V12-Rac1) was site-directed mutated based on the wild-type Rac1
cDNA template according to the the manufacturer’s instructions
(Stratagene, CA, USA). After DNA sequence con¢rmation, the dom-
inant positive form of Rac1 cDNA was cloned into a pIND mamma-
lian inducible expression vector driven by a ecdysone-responsive min-
imal promoter (Invitrogen).
2.4. Transfection and selection
Cells were transfected by the lipofectamine method according to the
manufacturer’s instructions (Life Technologies, Inc.). Brie£y, 1 Wg of
V12-Rac1-pIND plasmid was incubated with 6 Wl of lipofectamine
plus reagent at room temperature for 15 min, then 2 Wl of lipofect-
amine reagent added and incubated at room temperature. After 15
min, semicon£uent NIH3T3 cells were washed twice with 1UPBS,
then cells were incubated with DNA-lipofectamine-PLUS reagent
complexes at 37‡C at 5% CO2 for 4 h. After transfection, the mix
was aspirated, and cells were cultured with DMEM medium with 15%
FBS for an additional 24 h. Subsequently, cells were incubated with
complete medium containing 400 Wg/ml of G418 for 5 weeks. Cell
clones resistant to G418 were isolated and analyzed. For convenience,
one V12-Rac1-transfected cell clone was selected for further studies.
Transfected cells were routinely cultured in the presence of 400 Wg/ml
of G418. However, 2 days prior to and during the experiments, trans-
fected cells were cultured in complete DMEM medium without G418.
2.5. PI staining
The £oating and trypsin-detached NIH3T3 cells were collected and
washed once with ice-cold PBS and ¢xed in 70% cold ethanol. After
¢xation, cells were stained in PBS and PI (50 g/ml), RNase A (100 g/
ml), and 0.05% Triton X-100 for 45 min. DNA content of NIH3T3
cells was analyzed by £uorescent-activated cell sorting (FACSort, Bec-
ton Dickinson). At least 10 000 events were analyzed, and the percent-
age of cells in the sub-G1 population was calculated. Aggregates of
cell debris at the origin of the histogram were excluded from the
analysis of sub-G1 cells, as indicated in the legends to Figs. 2 and 5.
2.6. Preparation of protein lysates and Western blotting analysis
Total cell lysates were prepared on ice with lysis bu¡er (20 mM
Tris, pH 7.5, 100 mM NaCl, 2.5 mM EDTA, 1% Triton X-100, 0.5%
deoxycholate, 0.1% SDS, 5% glycerol, 10 mM NaF, 0.3 mM NaMo,
1 mM Na3VO4, and 0.5 mM 4-(2-aminoethyl)-benzenesulfonyl £uoride
hydrochloride). The cell lysates were centrifuged for 30 min at 4‡C,
and the supernatant was separated. The total protein concentration
was measured using a Bio-Rad protein assay kit. 30 Wg of total cel-
lular protein was subjected to SDS^PAGE, transferred to nitrocellu-
lose and immunoblotting with either anti-phospho-p38 or anti-p38
antibodies, anti-phospho-JNK or anti-JNK antibodies, and anti-phos-
pho-ERK or anti-ERK antibodies, respectively. The proteins were
detected by using enhanced chemiluminescence (ECL) reagents
(Amersham Pharmacia Biotech).
2.7. Release of cytochrome c
The cells were harvested in isotonic mitochondrial bu¡er (20 mM
sucrose, 20 mM HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA,
1 mM EGTA, 1 mM dithiothreitol, 10 mg/ml leupeptin, 1 mM phen-
ylmethylsulfonyl £uoride, 10 mg/ml aprotinin) and Dounce-homoge-
nized by 20 strokes. The homogenates were centrifuged at 1000Ug for
10 min at 4‡C to eliminate nuclei and unbroken cells. The resulting
supernatant was further centrifuged at 15 000Ug for 20 min at 4‡C to
obtain the mitochondrial fraction. The supernatant was further cen-
trifuged at 100 000Ug for 1 h at 4‡C to yield the ¢nal soluble cytosolic
fraction. Cytosolic and mitochondrial proteins were then subjected to
Western blot analysis using monoclonal cytochrome c antibody (Phar-
Mingen).
3. Results and discussion
3.1. Expression of V12-Rac1 prevented cisplatin-induced
apoptosis in NIH3T3 cells
To better understand the potential role of Rac1 in cell sur-
vival, NIH3T3 cells were stably transfected with Rac1 through
the V12-Rac1-pIND plasmid construct under control of the
ecdysone-responsive minimal promoter. Following selection
by G418 at the concentration of 400 Wg/ml for 5 weeks, we
isolated nine clones and analyzed V12-Rac1 expression which
can be turned on or o¡ by using ponasterone A. Among the
nine clones, we have chosen one V12-Rac1 expressing clone
(NIH3T3 V12-Rac1), which highly expressed V12-Rac1, for
further study in this investigation. Western blot analysis
showed that the addition of 5 WM ponasterone A e⁄ciently
induced expression of V12-Rac1. Expression of V12-Rac1 be-
came detectable within 12 h of treatment with ponasterone A
and the level of Rac1 protein continuously elevated for the
duration of ponasterone A treatment (Fig. 1). To investigate
whether expression of V12-Rac1 has any e¡ects on cell sur-
vival after exposure to cisplatin, cells were treated with or
without 5 WM ponasterone A for 24 h and then exposed to
20, 40 or 60 WM cisplatin. After 24 h cisplatin treatment, cells
were stained with PI and apoptosis was then measured using
FACScan £ow cytometry. As shown in Fig. 2, cisplatin caused
apoptosis of the V12-Rac1 non-expressing (Pon A (3))
NIH3T3 cells in a dose-dependent manner, with a concentra-
tion of 60 WM cisplatin resulting in death of greater than 85%
of the cells by 24 h of treatment. However, V12-Rac1 express-
ing (Pon A (+)) NIH3T3 cells exhibited signi¢cant resistance
to cisplatin. 24 h after addition of 60 WM cisplatin, less than
35% of cells have undergone apoptosis, which indicated that
the dominant active V12-Rac1 protected against cisplatin-in-
duced apoptosis in NIH3T3 cells.
3.2. Role of V12-Rac1 in mediating cytochrome c release in
cisplatin-treated cells
Recent studies on apoptosis have shown that cytochrome c
is released from the mitochondria following the exposure of
cells to certain stresses [32]. Therefore, the possibility as to
whether or not this pathway is activated by cisplatin was
investigated. If it was activated by cisplatin, the possibility
of this pathway being inhibited by V12-Rac1 expression was
examined. The Pon A (+) and Pon A (3) cells were treated
with 60 WM cisplatin for 24 h, after which we isolated mito-
chondria and cytosolic fraction and performed Western blot
analysis using an anti-cytochrome c monoclonal antibody to
determine the relative content of cytochrome c in mitochon-
dria versus the cytoplasm. In the Pon A (3) cells, cytochrome
c was present at high levels in the cytosolic fraction after
exposure to cisplatin (Fig. 3, top panel). However, in the
Pon (+) cells, a large amount of cytochrome c was present
in the mitochondrial fractions after exposure to cisplatin (Fig.
3, bottom panel).
The major pathways of apoptosis have been described in
recent years. One pathway is the Fas/APO-1-dependent path-
way. Fas/APO-1 interacts with the receptor-associated death
protease caspase-8, which eventually activates the downstream
e¡ector caspases [33,34]. The second pathway of apoptosis is a
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mitochondria-dependent one and results from release of cyto-
chrome c leading to caspase-9 activation through the apopto-
tic protease-activating factor-1 [35]. In this study, increased
cytochrome c levels were observed in the cytosol after expo-
sure to cisplatin in the Pon A (3) cells. This suggests that
cytochrome c release plays a role in mediating cisplatin-in-
duced apoptosis in NIH3T3 cells. The ability of V12-Rac1
expression to prevent this e¡ect suggests that V12-Rac1 acts
upstream of cytochrome c release to exert its survival in£u-
ence on the cisplatin-treated cells. To identify other factors
that may contribute to Rac1-controlled cell survival, the ex-
pression levels of a number of signaling molecules that have
been implicated in the regulation of cell death were tested.
However, no change in either anti-apoptotic (Bcl-2) or pro-
apoptotic (Fas, FasL, Bax) molecules was observed in the
V12-Rac1 cells as opposed to that observed in the control
cells following cisplatin treatment (data not shown).
3.3. E¡ect of V12-Rac1 expression on cisplatin-induced
MAPKs activation
To investigate the signaling pathways that mediate cispla-
tin-induced apoptosis in NIH3T3 cells, and to determine
whether V12-Rac1 a¡ects p38, JNK and ERK1/2 MAP kinase
activation in response to cisplatin, we examined whether or
not p38, JNK and ERK1/2 MAP kinase were activated by
cisplatin in the NIH3T3 cells, and whether or not V12-Rac1
modulates the activity of these MAP kinases. NIH3T3 V12-
Rac1 cells were treated with or without ponasterone A for 24
h, after which cells were exposed to 60 WM cisplatin for the
indicated times and the resulting cell lysates were subjected to
Western blot analysis using anti-phospho-p38 antibodies,
anti-phospho-JNK polyclonal antibodies and anti-ERK1/2
antibodies to detect phosphorylated p38, JNK and ERK1/2,
respectively. As shown in Fig. 4, cisplatin treatment induced
strong phosphorylation of p38, JNK and ERK1/2. Exposure
of the Pon A (3) cells to cisplatin resulted in an increase in
the level of phosphorylated p38 MAP kinase within 2 h with a
further increase in the phospho-p38 MAP kinase levels by 24
h (Fig. 4A, top panel). However, treatment of cells with po-
nasterone A markedly suppressed the cisplatin-induced p38
activation, and p38 activity was ¢rst detected 12 h after ex-
posure to cisplatin (Fig. 4A, middle panel). Densitometric
analyses showed p38 activation of the Pon A (3) cells at
12 h after cisplatin treatment to be 19-fold higher than p38
activity after treatment with cisplatin for 1 h, whereas peak
activation of p38 in Pon A (+) cells at 24 h was only seven-
fold higher than at 2 h after cisplatin treatment (Fig. 4A,
bottom panel). Cisplatin induced JNK activation of the Pon
A (3) cells starting at 8 h, peaking at 12 h and returning to
barely detectable levels by 24 h after treatment in the Pon A
Fig. 1. NIH3T3 cells were transfected with the V12-Rac1 inducible
expression vector, V12-Rac1-pIND. Cells were then selected in the
presence of G418 as described in Section 2. NIH3T3 V12-Rac1 cells
were prepared following ponasterone A (Pon A) treatment for the
indicated time. A total of 20 Wg cellular protein was separated on
12% SDS^PAGE, then the V12-Rac1 was analyzed, transferred to
Hybond ECL membrane, immunoreacted with anti-Rac1 antibody
and detected using ECL.
Fig. 2. A: The NIH3T3 V12-Rac1 cells were treated with (+) or
without (3) 5 WM ponasterone A (Pon A) for 24 h, after which
cells were incubated with di¡erent doses of cisplatin for 24 h. The
percentage of cells with hypodiploid (apoptotic) DNA content is in-
dicated (M1) as determined by PI staining and £ow cytometry.
B: Similar results were obtained in three additional experiments.
Bars represented S.D. values determined from three independent ex-
periments.
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(3) cells (Fig. 4B, top panel). Cisplatin induced JNK activa-
tion of the Pon A (+) cells starting at 12 h and continuing
through 24 h after treatment in the Pon A (+) cells (Fig. 4B,
middle panel). Densitometry analysis showed peak JNK acti-
vation of the Pon A (3) cells at 12 h to be six-fold higher than
at 2 h after treatment. JNK activation of the Pon A (+) cells
at 24 h after cisplatin treatment is seven-fold higher than JNK
activity after treatment with cisplatin for 8 h (Fig. 4C, bottom
panel). In contrast to p38 and JNK, V12-Rac1 expression did
not a¡ect ERK1/2 phosphorylation over a 24 h period follow-
ing cisplatin treatment (Fig. 4C). Stripping and reprobing the
same blot demonstrated that equal amounts of the p38, JNK
and ERK1/2 protein were expressed. Thus, these experiments
suggested that p38 and JNK but not ERK1/2 may be involved
in the V12-Rac1-mediated cell survival after exposure to cis-
platin in NIH3T3 cells.
3.4. p38 but not JNK and ERK1/2 are involved in
cisplatin-induced apoptosis
Cellular responses to many external stimuli involve the ac-
tivation of several types of MAPK signaling pathways includ-
ing ERK1/2, JNK, and p38 kinase. The ERK1/2 pathway is
regulated mostly by mitogenic stimuli, and leads to the pro-
duction of proteins required for cell growth and di¡erentia-
tion [36]. In contrast, JNK and p38 are activated primarily by
various stresses and are involved in cell transformation, stress
responses and apoptosis [37]. Because the V12-Rac1 expres-
sion decreased the p38 MAP kinase activity and delayed in-
crease of JNK in phosphorylation after exposure to cisplatin
in NIH3T3 cells, we next wanted to examine whether these
two MAP kinases are participating in the cisplatin-induced
apoptosis in NIH3T3 cells.
To address the potential involvement of p38 in cisplatin-
Fig. 3. The NIH3T3 V12-Rac1 cells were treated with (+) or with-
out (3) 5 WM ponasterone A (Pon A) for 24 h, after which cells
were incubated with or without (C) 60 WM cisplatin for an addition-
al 24 h. Proteins in cytosolic (top panel) and mitochondrial (bottom
panel) fractions of the cells were then subjected to Western blot
analysis using antibody against cytochrome c.
C
Fig. 4. The NIH3T3 V12-Rac1 cells were treated with (+) or with-
out (3) 5 WM ponasterone A (Pon A) for 24 h, after which cells
were incubated with 40 WM cisplatin for the indicated times. p38
(A), JNK (B) and ERK1/2 (C) activation were determined by West-
ern blot analysis using antibodies recognizing the phosphorylated
form of ERK1/2, p38 and JNK. Total ERK1/2, p38 and JNK pro-
tein levels were detected by Western blot analysis using anti-ERK1/
2, anti-p38 and anti-JNK antibodies, respectively. Fold activation
was determined for p-p38, p-ERK and p-JNK by scanning the
bands for densitometric analysis.
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induced apoptosis in NIH3T3 cells, the cells were pretreated
with p38 speci¢c inhibitor, SB203580 (10 WM), for 30 min.
Cells were then treated with 40 WM cisplatin for an additional
24 h, after which cells were stained with PI, and apoptosis was
then measured using FACScan £ow cytometry. As shown in
Fig. 5A,B, compared with the untreated cells, pretreatment
with 10 WM SB203580 resulted in a signi¢cantly lower apo-
ptotic cell population. We observed that pretreatment of
NIH3T3 cells with 10 WM SB20358 totally abolished p38
phosphorylation induced by cisplatin treatment (Fig. 5C, left
panel). To test that SB203580 was not inhibiting JNK activity
as well, we measured JNK activity and found that SB203580
had little e¡ect on cisplatin-induced JNK activation (data not
show). Therefore, these results suggest that the induction of
p38 activity is required, at least in part, for the cisplatin-in-
duced apoptosis.
To investigate the e¡ect of JNK on the cisplatin-induced
apoptosis, we conducted functional knock experiments using
antisense oligonucleotides to JNK1 (ISIS 15347) and JNK2
(ISIS 15354), which were phosphorothioate oligonucleotides
targeted to JNK1 and JNK2 mRNA to block the JNK/
SPAK pathway [38]. Repeat analyses of antisense oligonucleo-
tide functional knock of JNK were performed for compara-
tive purposes. NIH3T3 cells transiently transfected with either
0.2 WM each antisense JNK1 and JNK2 oligonucleotides
(JNK1+2AS) were cultured with 40 WM cisplatin for 24 h.
Antisense oligomers to JNK1/2 had no protective e¡ect on
the cisplatin-induced apoptosis (Fig. 5A,B), suggesting that
JNK activity is not involved in the cisplatin-induced apoptosis
in NIH3T3 cells. Evidence for transfection e⁄ciency and func-
tionality of the antisense oligonucleotide to JNK1/2, in com-
parison to scrambled oligonucleotides (ISIS 17552), exhibited
signi¢cantly reduced expression of JNK (Fig. 5C, right panel).
We also examined the role of ERK1/2 activation in the cis-
platin-induced apoptosis. As we expected, the ERK1/2 inhib-
itor U0126 had no e¡ect on cell survival (Fig. 5).
Cisplatin-induced apoptosis in NIH3T3 cells is potently in-
hibited by p38, probably acting via cytochrome c release from
the mitochondria. Therefore, the possibility as to whether or
not p38 activation exerted an e¡ect on cisplatin-induced cy-
tochrome c release from mitochondria was examined. As
shown in Fig. 6, 10 WM SB203580 e⁄ciently inhibited cyto-
chrome c release from the mitochondria following cisplatin
treatment. This implies that p38 activation is involved in the
release of cytochrome c during cisplatin-induced apoptosis.
p38 is associated with induction of apoptosis in numerous
cell types in response to di¡erent cellular stresses [39^41].
However, p38 activation may either prevent cell death or trig-
ger apoptosis depending upon the cell type and speci¢c death
stimulus [42]. Recently, two groups have reported that p38
activation following cisplatin treatment is involved in cispla-
tin-induced apoptosis [43,44] However, others have shown
that phosphorylated p38 has no e¡ect on cisplatin-induced
apoptosis [45,46]. Such varying results may depend on the
cell type speci¢city. However, in this study using NIH3T3
cells, the p38 MAP kinase inhibitor, SB203580, was quite
Fig. 5. A: NIH3T3 cells were pretreated with vehicle (DMSO), 10
WM SB203580 or 20 WM U0126 for 30 min followed by incubation
with or without 40 WM cisplatin. NIH3T3 cells transfected with 0.2
WM antisense JNK1 plus 0.2 WM antisense JNK2 (AS JNK1+2)
were treated with 40 WM cisplatin. After 24 h cisplatin treatment,
the cells were stained with PI, after which apoptosis was analyzed
by £ow cytometry. B: Similar results were obtained in three addi-
tional experiments. Bars represent S.D. values determined from
three independent experiments. C: Inhibition of cisplatin-induced
p38 and ERK1/2 phosphorylation by the p38 inhibitor SB203580
(SB: 10 WM) and the MEK1/2 inhibitor U0126 (U: 20 WM), respec-
tively. Attenuation of JNK protein levels by JNK1+2 antisense oli-
gonucleotides (AS), but not by sense oligonucleotide (S). p38,
ERK1/2 and JNK activities were carried out as in Fig. 4.
Fig. 6. NIH3T3 cells were pretreated with vehicle (DMSO) or 10
WM SB203580 (SB) for 30 min and cells were then treated with or
without 60 WM cisplatin. After 24 h, the cytosolic preparations were
tested for the accumulation of cytochrome c by Western blot analy-
sis, using a monoclonal antibody against cytochrome c.
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e¡ective in protecting NIH3T3 cells against cisplatin-mediated
apoptosis but not the JNK and ERK inhibitors.
Our experiments demonstrated that cisplatin treatment led
to apoptosis, which was associated with release of cytochrome
c from the mitochondria, and V12-Rac1 could inhibit cispla-
tin-induced apoptosis in the NIH3T3 cells. In addition, dom-
inant active V12-Rac1 attenuated p38 activity but not JNK
and ERK1/2 after exposure to cisplatin. Moreover, the p38
MAP kinase inhibitor, SB203580, was quite e¡ective in pro-
tecting NIH3T3 cells against cisplatin-mediated apoptosis.
The correlation of induced dominant active V12-Rac1 expres-
sion with increased cell survival as well as decreased p38 ac-
tivity after exposure to cisplatin suggests that raising the level
of V12-Rac1 may prevent cisplatin-induced apoptosis by sup-
pressing p38 activation. Further studies to identify the down-
stream target of the Rac cascade in the cisplatin signaling
pathway are recommended. Characterization of this pathway
will contribute to the understanding of how dominant active
Rac1 has a pro-survival role in cisplatin-induced apoptosis.
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